2 days ago · Julio Rojas on Proteomics Lays Groundwork for FTD Biomarkers 09 Feb 2025; Agustin Ibanez on Proteomics Lays Groundwork for FTD Biomarkers 09 Feb 2025; Charlotte Teunissen on Proteomics Lays Groundwork for FTD Biomarkers 09 Feb 2025; Franklin Tseng on Leqembi Maintenance Dosing Approved in the U.S. 07 Feb 2025; David Weisman on Leqembi Maintenance Dosing Approved in the U.S. 07 Feb 2025

Overview. Name: Leqembi Synonyms: Lecanemab-irmb, BAN2401, mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: BioArctic AB, Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble ...

08 Nov 2024. Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease conference, held October 29-November 1 in Madrid. Starting at a low dose, and stepping it up over the first four months, cut the rate of ARIA-E …

Sep 23, 2024 · Overview. Name: ALZ-801 Synonyms: valiltramiprosate, NRM-8499, homotaurine prodrug, 3-APS Therapy Type: Small Molecule Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Alzheon Inc. Background. This is a prodrug of homotaurine, a modified amino acid previously developed under the names tramiprosate and Alzhemed™.

On new studies, Lilly scientists presented efforts to gather real-world data on donanemab’s effectiveness, and debuted the Phase 3 trial design for donanemab’s successor, remternetug, which patients can inject under the skin. During CTAD, news broke that Eisai had completed its Food and Drug Administration submission for subcutaneous lecanemab. . This formulation would be given as a weekly ...

Dec 5, 2024 · Suzanne Schindler Washington University; John Morris Washington University School of Medicine; Posted: 08 Dec 2024 Aisen et al. suggest the possibility of treating individuals with biomarker evidence of amyloid plaques with anti-amyloid treatments, regardless of whether these individuals have cognitive impairment, and they provide a strong scientific rationale for this approach based on the ...

Jan 8, 2025 · Overview. Name: E2814 Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2/3) Company: Eisai Co., Ltd. Background. This humanized, monoclonal IgG1 antibody recognizes an HVPGG epitope in the microtubule-binding domain near the mid-domain of tau.

04 May 2023. Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly press release.The treatment slowed decline on the primary outcome, the combined cognitive and functional measure iADRS, by more than a third.

Jul 10, 2024 · Overview. Name: Latozinemab Synonyms: AL001, GSK4527223 Therapy Type: Immunotherapy (passive) Target Type: Other Condition(s): Frontotemporal Dementia, Amyotrophic Lateral Sclerosis U.S. FDA Status: Frontotemporal Dementia (Phase 3), Amyotrophic Lateral Sclerosis (Inactive) Company: Alector, GlaxoSmithKline (GSK) Background. AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal ...

21 Nov 2024. Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid.In answering a question that has been raised often in the last few years, Schindler said that the field has reached a tipping point, and that highly accurate plasma tests deserve much of ...